FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007103166> ?p ?o ?g. }

• W2007103166 endingPage "12" @default.
• W2007103166 startingPage "1" @default.
• W2007103166 abstract "The term cancer chemoprevention refers to the prevention of prolongation of carcinogenesis by intervention with drugs prior to the malignant (i.e., invasive) stage. The development of chemopreventive drugs is the major objective of the Chemoprevention Branch of the National Cancer Institute. Neoplastic lesions of the urinary bladder present a unique opportunity for evaluating chemopreventive agents because of (1) the accessibility of the lesions to observation and biopsy, and (2) those patients who have been successfully treated for a primary lesion represent a population at unusually high risk for recurrence and/or progression. Although 70–80% of bladder cancers initially present as superficial, papillary transitional cell neoplasms with limited potential for invasion, the incidence of recurrence is high after resection (60–75%). Recurrent tumors are highly unpredictable, and may be of higher grade of stage (progression). Although recurrence is responsible for high treatment-related morbidity, progression represents the greatest potential for mortality. Thus, potential chemopreventive agents considered here would modulate bladder carcinogenesis from initiation of normal-appearing tissue through progression of superficial tumors. Clinical trials of chemopreventive drugs involve healthy target populations, and the endpoints are reduced cancner incidence or mortality, reduced/eliminated precancerous lesions or increased latency, with none to minimal toxicity. Since cancers may not appear for 20–30 years, two of the most difficult aspects of testing these drugs in intervention trials are the long observation poeriods and large study populations required to measure cancer incidence reduction. However, observing the regression or recurrence of superficial bladder lesions (TIS, T1, Ta) requires relatively short time periods. Thus, these lesions lend themselves to the investigation of intermediate biomarkers, defined as morphologic and/or molecular alterations in tissue between initiation and tumor invasion. It is hypothesized that modulation of one or more biomarkers would interrupt carcinogenesis and result in a decrease in cancer incidence. Thus, evaluation of biomarkers as surrogate endpoints would allow bladder trials to be of even shorter duration, use fewer subjects and be lower in cost. In addition, intermediate biomarkers could predict which superficial lesions (or normal-appearing tissue) have the greatest potential for neoplastic progression. Development of strategies for the design of intrvention trials for bladder cancer and review of the current status of intermediate biomarkers in the bladder, and methods for their validation, are major objectives of this workshop." @default.
• W2007103166 created "2016-06-24" @default.
• W2007103166 creator A5017000224 @default.
• W2007103166 creator A5025231476 @default.
• W2007103166 creator A5026803383 @default.
• W2007103166 creator A5048308941 @default.
• W2007103166 creator A5054125731 @default.
• W2007103166 date "1992-01-01" @default.
• W2007103166 modified "2023-09-25" @default.
• W2007103166 title "Development of chemopreventive agents for bladder cancer" @default.
• W2007103166 cites W1976504060 @default.
• W2007103166 cites W197652651 @default.
• W2007103166 cites W1991308042 @default.
• W2007103166 cites W1994856847 @default.
• W2007103166 cites W1995317658 @default.
• W2007103166 cites W2000169972 @default.
• W2007103166 cites W2001258296 @default.
• W2007103166 cites W2005740472 @default.
• W2007103166 cites W2011734385 @default.
• W2007103166 cites W2016089478 @default.
• W2007103166 cites W2017437947 @default.
• W2007103166 cites W2030002149 @default.
• W2007103166 cites W2030726570 @default.
• W2007103166 cites W2034612034 @default.
• W2007103166 cites W2043486264 @default.
• W2007103166 cites W2045209848 @default.
• W2007103166 cites W2063706311 @default.
• W2007103166 cites W2078804129 @default.
• W2007103166 cites W2090701312 @default.
• W2007103166 cites W2257428454 @default.
• W2007103166 cites W93410323 @default.
• W2007103166 cites W94207824 @default.
• W2007103166 doi "https://doi.org/10.1002/jcb.240501303" @default.
• W2007103166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1305671" @default.
• W2007103166 hasPublicationYear "1992" @default.
• W2007103166 type Work @default.
• W2007103166 sameAs 2007103166 @default.
• W2007103166 citedByCount "10" @default.
• W2007103166 crossrefType "journal-article" @default.
• W2007103166 hasAuthorship W2007103166A5017000224 @default.
• W2007103166 hasAuthorship W2007103166A5025231476 @default.
• W2007103166 hasAuthorship W2007103166A5026803383 @default.
• W2007103166 hasAuthorship W2007103166A5048308941 @default.
• W2007103166 hasAuthorship W2007103166A5054125731 @default.
• W2007103166 hasConcept C120665830 @default.
• W2007103166 hasConcept C121332964 @default.
• W2007103166 hasConcept C121608353 @default.
• W2007103166 hasConcept C126322002 @default.
• W2007103166 hasConcept C142724271 @default.
• W2007103166 hasConcept C143998085 @default.
• W2007103166 hasConcept C146357865 @default.
• W2007103166 hasConcept C151730666 @default.
• W2007103166 hasConcept C2779762690 @default.
• W2007103166 hasConcept C2780352672 @default.
• W2007103166 hasConcept C2908647359 @default.
• W2007103166 hasConcept C535046627 @default.
• W2007103166 hasConcept C555283112 @default.
• W2007103166 hasConcept C61511704 @default.
• W2007103166 hasConcept C71924100 @default.
• W2007103166 hasConcept C86803240 @default.
• W2007103166 hasConcept C99454951 @default.
• W2007103166 hasConceptScore W2007103166C120665830 @default.
• W2007103166 hasConceptScore W2007103166C121332964 @default.
• W2007103166 hasConceptScore W2007103166C121608353 @default.
• W2007103166 hasConceptScore W2007103166C126322002 @default.
• W2007103166 hasConceptScore W2007103166C142724271 @default.
• W2007103166 hasConceptScore W2007103166C143998085 @default.
• W2007103166 hasConceptScore W2007103166C146357865 @default.
• W2007103166 hasConceptScore W2007103166C151730666 @default.
• W2007103166 hasConceptScore W2007103166C2779762690 @default.
• W2007103166 hasConceptScore W2007103166C2780352672 @default.
• W2007103166 hasConceptScore W2007103166C2908647359 @default.
• W2007103166 hasConceptScore W2007103166C535046627 @default.
• W2007103166 hasConceptScore W2007103166C555283112 @default.
• W2007103166 hasConceptScore W2007103166C61511704 @default.
• W2007103166 hasConceptScore W2007103166C71924100 @default.
• W2007103166 hasConceptScore W2007103166C86803240 @default.
• W2007103166 hasConceptScore W2007103166C99454951 @default.
• W2007103166 hasIssue "S16I" @default.
• W2007103166 hasLocation W20071031661 @default.
• W2007103166 hasLocation W20071031662 @default.
• W2007103166 hasOpenAccess W2007103166 @default.
• W2007103166 hasPrimaryLocation W20071031661 @default.
• W2007103166 hasRelatedWork W1580426574 @default.
• W2007103166 hasRelatedWork W1979321249 @default.
• W2007103166 hasRelatedWork W2075509189 @default.
• W2007103166 hasRelatedWork W2089620537 @default.
• W2007103166 hasRelatedWork W2234237117 @default.
• W2007103166 hasRelatedWork W2275480158 @default.
• W2007103166 hasRelatedWork W2356105190 @default.
• W2007103166 hasRelatedWork W2371214482 @default.
• W2007103166 hasRelatedWork W3095306390 @default.
• W2007103166 hasRelatedWork W4238089809 @default.
• W2007103166 hasVolume "50" @default.
• W2007103166 isParatext "false" @default.
• W2007103166 isRetracted "false" @default.
• W2007103166 magId "2007103166" @default.
• W2007103166 workType "article" @default.